Alpha 2.0
Login Register
» Articles » PMID: 38300898

Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2024 Feb 1
PMID 38300898
Authors
Maria C Foss-Freitas
Salman Imam
Adam Neidert
Anabela Dill Gomes
David T Broome
Elif A Oral
Affiliations
Soon will be listed here.
Abstract

Objective: Glucagon-like peptide 1 receptor agonists (GLP-1RA) are widely used for the management of diabetes mellitus (DM), but their efficacy in familial partial lipodystrophy (FPLD) is unknown. In this retrospective study, we evaluated the effect of GLP-1RA in patients with FPLD.

Research Design And Methods: We analyzed data, reported with SDs, from 14 patients with FPLD (aged 58 ± 12 years; 76.47% female) and 14 patients with type 2 DM (aged 58 ± 13 years; 71% female) before and 6 months after starting GLP-1RA.

Results: We observed reduction in weight (95 ± 23 to 91 ± 22 kg; P = 0.002), BMI (33 ± 6 to 31 ± 6 kg/m2; P = 0.001), HbA1c (8.2% ± 1.4% to 7.7% ± 1.4%; P = 0.02), and fasting glucose (186 ± 64 to 166 ± 53 mg/dL; P = 0.04) in patients with FPLD. The change in triglycerides after treatment was greater in the FPLD group compared with the DM group (P = 0.02). We noted acute pancreatitis in two case subjects with FPLD with longer therapy.

Conclusions: Our study demonstrates the relative safety and effectiveness of GLP-1RA in patients with FPLD.

Citing Articles

Response to Comment on Foss-Freitas et al. Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy. Diabetes Care 2024;47:653-659.

Foss-Freitas M, Broome D, Oral E Diabetes Care. 2025; 48(3):e32.

PMID: 39977641 PMC: 11870280. DOI: 10.2337/dci24-0080.

Safety and effectiveness in an uncontrolled setting of glucagon-like-peptide-1 receptor agonists in patients with familial partial lipodystrophy: Real-life experience from a national reference network.

Lamothe S, Belalem I, Vantyghem M, Nobecourt E, Mosbah H, Beliard S Diabetes Obes Metab. 2025; 27(4):1815-1825.

PMID: 39829337 PMC: 11885082. DOI: 10.1111/dom.16175.

Familial partial lipodystrophy resulting from loss-of-function PPARγ pathogenic variants: phenotypic, clinical, and genetic features.

Soares R, da Silva M, de Melo Campos J, Lima J Front Endocrinol (Lausanne). 2024; 15:1394102.

PMID: 39398333 PMC: 11466747. DOI: 10.3389/fendo.2024.1394102.

References
1.
Tong J, Sandoval D . Is the GLP-1 system a viable therapeutic target for weight reduction?. Rev Endocr Metab Disord. 2011; 12(3):187-95. PMC: 3145813. DOI: 10.1007/s11154-011-9170-8. View
2.
Hernandez A, Green J, Janmohamed S, DAgostino Sr R, Granger C, Jones N . Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018; 392(10157):1519-1529. DOI: 10.1016/S0140-6736(18)32261-X. View
3.
Valerio C, de Almeida J, Moreira R, Aguiar L, Siciliano P, Carvalho D . Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2. Diabetol Metab Syndr. 2017; 9:26. PMC: 5404683. DOI: 10.1186/s13098-017-0226-0. View
4.
Brown R, Oral E, Cochran E, Araujo-Vilar D, Savage D, Long A . Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. Endocrine. 2018; 60(3):479-489. PMC: 5936645. DOI: 10.1007/s12020-018-1589-1. View
5.
Brown R, Araujo-Vilar D, Cheung P, Dunger D, Garg A, Jack M . The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab. 2016; 101(12):4500-4511. PMC: 5155679. DOI: 10.1210/jc.2016-2466. View